Our Approach
Focused on making today better for people living with rare disease.
We are a commercialization engine built to bring proven treatments to rare disease communities with serious unmet need. Our strength lies in the fundamentals: deep expertise across regulatory, manufacturing, access, and community partnerships supported by the right talent, culture, and systems to act decisively. When we believe in an asset, we are prepared to move it forward efficiently, responsibly, and with respect for the people who need it most.
There is no single playbook in rare disease. Every community is different. That’s why our approach is tailored, not templated. We combine end-to-end execution with close listening to learn directly from advocates, researchers, clinicians, patients, and families. By understanding each community on its own terms, we are better able to design life-changing solutions that meet people where they are.
We are a commercialization engine with a focus on products that are clearly differentiated from an efficacy standpoint. ”
A history of results.
A culture of impact.
As the United States rare disease affiliate of an established global pharmaceutical company, we combine a flexible, entrepreneurial approach with a longstanding record of delivering meaningful results.
Global Legacy
Our parent company, Italfarmaco Group, is a private, global company with a long history of developing innovative medicines used by patients around the world. Founded in 1938 in Milan, Italy, Italfarmaco now operates in more than 90 countries across five continents, advancing research to address unmet medical needs across a broad range of therapeutic areas.
Italfarmaco Group’s Reach
90+
Countries
Across 5 Continents
3,800
Group Employees
80+
Year in Business
100%
Family Ownership
4
Research & Development Hubs
Italy (2) + Spain (2)
6
Manufacturing Sites
Milan, Frosinone, Madrid, Barcelona, Salvador de Bahia + Santiago de Chile
300+
Research + Development
Employees
Entrepreneurial Drive
ITF Therapeutics was established in January 2024 with headquarters in Concord, MA to develop and commercialize rare disease treatments in the United States. Within six months of the company’s launch, we secured FDA approval for our first product and made it commercially available. By our first anniversary, we had reached well over a thousand patients in the US with commercial supply. As our impact grows, we maintain close partnerships with the patient, physician, and payer communities and remain flexible and nimble so our work can be continuously informed by their perspectives.
Following the successful FDA approval and launch of our first commercial product, we are now focused on leveraging our team’s expertise to build on this historic advance for additional rare disease communities.